Perspective Canadian company offers you to heal Cystitis

The first day of the week demonstrated various market indexes: DJIA -0.10%, NASDAQ: + 0.14%, S & P500 -0.04%. Biotech showed a slight increase: NASDAQ Biotechnology (^ NBI) + 0.49%.

The excellent growth showed: Ultragenyx Pharmaceutical Inc. (RARE) + 10.44%, bluebird bio, Inc. (BLUE) + 10.61%, Collegium Pharmaceutical, Inc. (COLL) 10.10%, Pacira Pharmaceuticals, Inc. (PCRX) + 7.44%, Aquinox Pharmaceuticals Inc. (AQXP) + 19.83%. MannKind Corp. (MNKD) continued its growth (+ 10.30%).

Shares slumped for Neos Therapeutics, Inc. (NEOS) -19.88%, Enanta Pharmaceuticals, Inc. (ENTA) -8.40% and Avalanche Biotechnologies, Inc. (AAVL) -13.00%.
Today Aquinox Pharmaceuticals Inc. (AQXP) increased at once $ 2.08 (+ 19.83%)! The trading volume was 602,000 shares, instead of the average 266,000. The company’s capitalization is $ 216 million. The minimum share price during last52 weeks: $ 1.38, while the maximum — $ 55.75.

Aquinox Pharmaceuticals Inc. — biopharmaceutical company engaged in the discovery and development targeted treatments in the area of inflammatory and immuno-oncology. The company was founded in 2003, its headquarters is located in Vancouver (Canada).

IVAO ratings for Aquinox:
Science Rating: 
Financial Rating: 
Total rating: 

Aquinox’s leading drug candidate is AQX–1125 — small molecule activator of SHIP1 enzyme, which plays a key role in inflammation. In 2016 Aquinox begins phase III clinical trials for this drug candidate to treat bladder pain syndrome/interstitial cystitis — a chronic disease, which affects millions of people. The company puts a lot of hope on AQX–1125, moreover, the current clinical trials show good results.

Last year, the company’s EBITDA was — $ 23.44 million. Cash on balanced account: $ 117.4 million, which allows to work quietly for 5 years, considering the operating costs (cash flow: — $ 23,79 million).

Our forecast for stock prices: $ 16.
Learn how to invest in this company. Our experts will provide you all necessary support. Submit your application.
You can order more detailed analysis on the company, which includes:

  • Analysis of financial performance
  • Overview of the market and competitors
  • Selection panel of experts on the drug and other drug companies
  • Estimation of prospects of subsequent phases of testing

Buy analytical review or contact our sales department:
Phone: +7 812 332 20 08
IVAO analysts: Andrew Voronkov, Ph. D., Alexander Novikov, MBA.

Log in or sign up on  to add a comment to scientific problem you are interested in!
Comments (0)